Product Specification
| Host |
Human |
| Antigen |
CD40 |
| Synonyms |
Tumor necrosis factor receptor superfamily member 5; B-cell surface antigen CD40; Bp50; CD40L receptor; CDw40; TNFRSF5 |
| Location |
Cell membrane |
| Accession |
P25942 |
| Clone Number |
S-R443 |
| Antibody Type |
Recombinant mAb |
| Isotype |
IgG |
| Application |
FCM |
| Reactivity |
Hu |
| Positive Sample |
Human PBMC |
| Purification |
Protein A |
| Concentration |
0.002mg/ml |
| Conjugation |
Alexa Fluor® 647 |
| Physical Appearance |
Liquid |
| Storage Buffer |
PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage |
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application |
dilution |
species |
| FCM |
5 μl per million cells in 100μl volume |
Hu |
Background
CD40 is a member of the tumor necrosis factor receptor superfamily and is primarily involved in regulating immune responses. It is highly expressed on cells such as B cells, dendritic cells (DCs), and monocytes, and plays a crucial role in linking innate and adaptive immunity. CD40 signaling is a key trigger in the maturation process of monocytes, mainly driving differentiation into M1-type macrophages and DCs. On DC surfaces, CD40 is involved in promoting the production of cytokines and chemokines, inducing the expression of costimulatory molecules, and enhancing antigen cross-presentation. CD40 is also expressed on various types of cells, including fibroblasts, endothelial cells, and certain hematopoietic and epithelial tumor cells. In the context of CAR-T cell therapy, the expression of CD40L on the surface of CAR-T cells has been explored to enhance their anti-tumor functions.
